Dr. Agrawals Eye Hospital Intrinsic Value
Dr. Agrawals Eye Hospital (DRAGARWQ) median intrinsic value is ₹1770.00 from 9 valuation models (range ₹972–₹2581), vs current price ₹4857.75 — -63.6% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit DRAGARWQ company profile.
DRAGARWQ Valuation Methods Summary — DCF, Graham Number & P/E
Dr. Agrawals Eye Hospital intrinsic value across 9 models vs current price ₹4857.75 — upside/downside and value range per method. Browse Dr. Agrawals Eye Hospital annual reports for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1770.00 | ₹1416.00 - ₹2124.00 | -63.6% | EPS: ₹147.50, Sector P/E: 12x |
| Book Value Method | asset | ₹971.55 | ₹874.39 - ₹1068.70 | -80.0% | Book Value/Share: ₹420.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹1457.33 | ₹1311.60 - ₹1603.06 | -70.0% | Revenue/Share: ₹910.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1943.10 | ₹1748.79 - ₹2137.41 | -60.0% | EBITDA: ₹148.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹2580.83 | ₹2064.66 - ₹3097.00 | -46.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2360.00 | ₹2124.00 - ₹2596.00 | -51.4% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹1457.33 | ₹1311.60 - ₹1603.06 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 8.6x |
| ROE Based Valuation | profitability | ₹2428.88 | ₹2185.99 - ₹2671.77 | -50.0% | ROE: 33.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1457.33 | ₹1311.60 - ₹1603.06 | -70.0% | EPS: ₹147.50, BVPS: ₹420.00 |
DRAGARWQ Intrinsic Value vs Market Price — All Valuation Models
Dr. Agrawals Eye Hospital fair value range ₹972–₹2581 vs current market price ₹4857.75 across 9 valuation models. Compare with DRAGARWQ fair price to assess whether the stock is under or overvalued.
DRAGARWQ Intrinsic Value Analysis — Undervalued or Overvalued?
Dr. Agrawals Eye Hospital median intrinsic value ₹1770.00, current price ₹4857.75 — Trading Above Calculated Value by 63.6%, margin of safety -100.0%.
What is the intrinsic value of DRAGARWQ?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Dr. Agrawals Eye Hospital (DRAGARWQ) is ₹1770.00 (median value). With the current market price of ₹4857.75, this represents a -63.6% variance from our estimated fair value.
The valuation range spans from ₹971.55 to ₹2580.83, indicating ₹971.55 - ₹2580.83.
Is DRAGARWQ undervalued or overvalued?
Based on our multi-method analysis, Dr. Agrawals Eye Hospital (DRAGARWQ) appears to be trading above calculated value by approximately 63.6%.
DRAGARWQ Financial Health — Key Ratios vs Industry Benchmarks
Dr. Agrawals Eye Hospital financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.18 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 33.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 32.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.74x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
DRAGARWQ Cash Flow Quality — Operating & Free Cash Flow
Dr. Agrawals Eye Hospital operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹95 Cr | ₹29 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹90 Cr | ₹55 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹70 Cr | ₹35 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹57 Cr | ₹34 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹34 Cr | ₹29 Cr | Positive Free Cash Flow | 8/10 |